Skip to main content
SpringerLink
Log in

Mesalazine pharmacokinetics and NAT2 phenotype

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

Mesalazine undergoes extensive metabolism by N-acetylation. While there is some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2 (NAT2) in vivo has not been tested.

Methods

In two studies in healthy young Caucasians, NAT2 phenotyping was carried out using a caffeine metabolic ratio in urine 4-6 h postdose. In study A, 1,000 mg mesalazine doses were given thrice daily for 5 days, and urine and blood samples were drawn during the last dosing interval. In study B, a 1,000 mg single dose was given, and samples were taken for 48 h postdose. Pharmacokinetics of mesalazine and N-acetylmesalazine (LC-MS/MS) were calculated by noncompartmental methods.

Results

NAT2 phenotype could be allocated unequivocally in 21 slow and 5 rapid acetylators in study A, and in 9 slow and 8 rapid acetylators in study B. Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 µg/mL·h (51%) [12.0 µg/mL·h (52%)], N-acetylmesalazine AUC 27.7 µg/mL·h (32%) [30.5 µg/mL·h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)]. Values in study B were as follows: mesalazine AUC 3.45 µg/mL·h (113%) [2.36 µg/mL·h (87%)], N-acetylmesalazine AUC 21.3 µg/mL·h (29%) [18.0 µg/mL·h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)]. Higher AUC and Ae values for mesalazine in steady state study indicate saturation of mesalazine metabolism. Statistics provided no evidence for a true difference in mesalazine pharmacokinetics between slow and rapid acetylators, and no significant correlation between NAT2 activity and any mesalazine pharmacokinetic parameter was found.

Conclusion

NAT2 has no major role in human metabolism of mesalazine in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Klotz U, Maier KE (1987) Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci 32(12 Suppl):46S–50S

    Article  PubMed  CAS  Google Scholar 

  2. Estrada-Rodgers L, Levy GN, Weber WW (1998) Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells. Drug Metab Dispos 26(5):502–505

    PubMed  CAS  Google Scholar 

  3. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ et al (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14(8):1633–1638

    Article  PubMed  CAS  Google Scholar 

  4. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME (2000) Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 54(1):19–29

    Article  PubMed  CAS  Google Scholar 

  5. Fischer C, Maier K, Stumpf E, von Gaisberg U, Klotz U (1983) Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 25(4):511–515

    Article  PubMed  CAS  Google Scholar 

  6. Azad Khan AK, Nurazzaman M, Truelove SC (1983) The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet 20(1):30–36

    Article  PubMed  CAS  Google Scholar 

  7. Bondesen S, Hegnhoj J, Larsen F, Hansen SH, Hansen CP, Rasmussen SN (1991) Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci 36(12):1735–1740

    Article  PubMed  CAS  Google Scholar 

  8. Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, Soderberg HN et al (1989) Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 97(1):38–41

    PubMed  CAS  Google Scholar 

  9. Ricart E, Taylor WR, Loftus EV, O’Kane D, Weinshilboum RM, Tremaine WJ et al (2002) N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 97(7):1763–1768

    Article  PubMed  CAS  Google Scholar 

  10. Hausmann M, Paul G, Menzel K, Brunner-Ploss R, Falk W, Scholmerich J et al (2008) NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol 46(3):259–265

    Article  PubMed  CAS  Google Scholar 

  11. Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J et al (2004) Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol 60(1):17–21

    Article  PubMed  CAS  Google Scholar 

  12. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M et al (2005) Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49(5):1733–1738

    Article  PubMed  CAS  Google Scholar 

  13. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL et al (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10(12):1239–1248

    PubMed  CAS  Google Scholar 

  14. Jetter A, Kinzig-Schippers M, Illauer M, Tomalik-Scharte D, Sörgel F, Fuhr U (2004) When should urine samples for NAT2 phenotyping with caffeine be collected? Clin Pharmacol Ther 75(2):P69

    Article  Google Scholar 

  15. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81(2):270–283

    Article  PubMed  CAS  Google Scholar 

  16. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C et al (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6(2):159–176

    Article  PubMed  CAS  Google Scholar 

  17. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA et al (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42(3):402–409

    Article  PubMed  CAS  Google Scholar 

  18. Sandborn WJ, Hanauer SB (2003) Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17(1):29–42

    Article  PubMed  CAS  Google Scholar 

  19. Hardy JG, Harvey WJ, Sparrow RA, Marshall GB, Steed KP, Macarios M et al (1993) Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 33(8):712–718

    PubMed  CAS  Google Scholar 

  20. Ireland A, Priddle JD, Jewell DP (1990) Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci (Lond) 78(1):105–111

    CAS  Google Scholar 

  21. Mahid SS, Colliver DW, Crawford NP, Martini BD, Doll MA, Hein DW et al (2007) Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Med Genet 8:28

    Article  PubMed  CAS  Google Scholar 

  22. Delomenie C, Fouix S, Longuemaux S, Brahimi N, Bizet C, Picard B et al (2001) Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol 183(11):3417–3427

    Article  PubMed  CAS  Google Scholar 

  23. van Hogezand RA, Kennis HM, van Schaik A, Koopman JP, van Hees PA, van Tongeren JH (1992) Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions. Eur J Clin Pharmacol 43(2):189–192

    Article  PubMed  Google Scholar 

  24. Walraven JM, Trent JO, Hein DW (2008) Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab Rev 40(1):169–184

    Article  PubMed  CAS  Google Scholar 

  25. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH (1999) Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 58(11):1759–1764

    Article  PubMed  CAS  Google Scholar 

  26. Dilger K, Trenk D, Rossle M, Cap M, Zahringer A, Wacheck V et al (2007) A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. Eur J Clin Invest 37(7):558–565

    Article  PubMed  CAS  Google Scholar 

  27. Muller AF, Stevens PE, McIntyre AS, Ellison H, Logan RF (2005) Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 21(10):1217–1224

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany

    Hendrik Lück, Alexander Jetter & Uwe Fuhr

  2. ITECRA Institute for Tailored Early Clinical Research and Advice GmbH & Co. KG, Cologne, Germany

    Hendrik Lück

  3. Institute of Biomedical and Pharmaceutical Research (IBMP), Nürnberg-Heroldsberg, Germany

    Martina Kinzig & Fritz Sörgel

  4. Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland

    Alexander Jetter

  5. Department of Pharmacology, University of Duisburg – Essen, Universitätsklinikum Essen, Essen, Germany

    Fritz Sörgel

  6. Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Str. 24, 50931, Köln, Germany

    Uwe Fuhr

Authors
  1. Hendrik Lück
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Kinzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Jetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uwe Fuhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fritz Sörgel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Fuhr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lück, H., Kinzig, M., Jetter, A. et al. Mesalazine pharmacokinetics and NAT2 phenotype. Eur J Clin Pharmacol 65, 47–54 (2009). https://doi.org/10.1007/s00228-008-0550-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0550-2

Keywords

Search

Navigation